Articles By Estel Grace Masangkay

  1. TSRI's MS Drug Also Shows Promise In Ulcerative Colitis 10/30/2014

    The Scripps Research Institute (TSRI) reported that results from the Phase 2 study of RPC1063, a drug discovered at the Institute, show RPC1063’s potential in the treatment of ulcerative colitis (UC).

  2. Salk Scientists Identify Protein As HIV-1 Therapeutic Target 10/30/2014

    A team of scientists from the Salk Institute for Biological Studies reported that they have identified a protein that could be exploited as HIV-1’s Achilles heel.

  3. GSK Expands Drug Research Partnership With Five Prime 10/30/2014

    Five Prime Therapeutics, a clinical stage biotech firm, announced that its partner GlaxoSmithKline has extended their drug research collaboration in respiratory diseases for another year and a half.

  4. J&J Joins Race To Develop And Deliver Ebola Vaccine 10/28/2014

    Johnson & Johnson announced that it is committing up to $200 million to speed and expand its production of an Ebola vaccine under development at its subsidiary Janssen Pharmaceuticals.

  5. EMA Grants Orphan Status To GW's Epidiolex For Epilepsy 10/27/2014

    Biopharmaceutical company GW Pharmaceuticals announced that it has received Orphan Drug Designation from the European Medicines Agency (EMA) for Epidiolex as treatment for rare form of epilepsy Dravet syndrome.

  6. Roche, Pharmacyclics Enter Cancer Combo Therapy Deal 10/24/2014

    Pharmacyclics announced that it has signed into a master clinical drug supply agreement with Roche for an initial Phase 3 study of Pharmacyclics’ Imbruvica and Roche/Genentech’s Gazyva as a combination cancer therapy.

  7. Roche Invests $3 Billion In Basel R&D Site 10/24/2014

    Roche announced its commitment to invest 3 billion Swiss francs ($3.2 billion) over the next 10 years for its development plans that will include the construction of a new R&D site in Basel, Switzerland.

  8. Halozyme Gets FDA OK For 2 New Production Sites For Hylenex 10/23/2014

    Biopharmaceutical company Halozyme Therapeutics announced that it has received the approval of the U.S. Food and Drug Administration (FDA) for its new contract manufacturing facilities that will be used to produce Hylenex recombinant (hyaluronidase human injection).

  9. Immunomedics Gets EU Orphan Status For Pancreatic Cancer ADC 10/23/2014

    Clinical stage biopharmaceutical company Immunomedics announced that it has received Orphan Drug status for isactuzumab govitecan (IMMU-132) for the treatment of pancreatic cancer.

  10. Karolinska Institutet Links With Moderna In mRNA Therapeutics 10/22/2014

    Moderna Therapeutics, Karolinska Institutet (KI), and Karolinska University Hospital (KUH) have joined forces to discover and develop drugs using messenger RNA (mRNA) Therapeutics technology.